Asciminib as a Robust Treatment Option for BCR::ABL1 T315I-Mutated Chronic Myeloid Leukemia: Final Phase 1 Trial Outcomes
AsciminibChronic Myeloid LeukemiaBCR::ABL1 T315I mutationMajor Molecular ResponseChronic Myeloid Leukemia
Highlight
This phase 1 trial provides final long-term data validating asciminib’s targeted inhibition of the ABL1 myristoyl pocket to overcome resistance caused by the T315I mutation in chronic-phase chronic myeloid leukemia (CML-CP). After up to approximately six years of treatment, over half the patients achieve and sustain major molecular response, with a stable safety profile and low discontinuation.
Key points include:
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.